TriSalus Life Sciences, Inc. (TLSI) TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
TriSalus Life Sciences, Inc. NASDAQ:TLSI Healthcare · Medical - Devices
Mkt Cap $227.83M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences announced that CEO Mary Szela and CFO David Patience will participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum.
Management will host one-on-one meetings and present a corporate overview on Wednesday, November 11, at 11:30 a.m. ET, with a live webcast and 90-day replay available.
The notice contains no new financial or clinical results; it is a routine investor-outreach announcement.
• 3d ago AI analysis › Press Release
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences will host a conference call and webcast on November 10, 2026, at 8:30 AM ET to discuss Q3 2026 financial results for the quarter ended September 30.
A results press release will be issued prior to the call, with registration via an online form and a replay available on the investor relations site.
This is a scheduling notice only and contains no financial figures; the company also noted it is in the final stages of data completion for several phase 1 nelitolimod trials and will explore partnership opportunities.
• 12d ago AI analysis › Press Release
TriSalus Life Sciences Receives FDA Clearance for TriNav® Advance, Strengthening Comprehensive Pressure-Enabled Drug Delivery™ (PEDD™) Portfolio for Liver Embolization
TriSalus Life Sciences received FDA 510(k) clearance for TriNav Advance, the newest addition to its Pressure-Enabled Drug Delivery portfolio for liver embolization.
The new device adds access to small, distal vessels via a compatible microcatheter, and supports embolization procedures beyond the liver; a limited market release is planned over the coming weeks.
CEO Mary Szela said the clearance broadens the portfolio across the full range of liver embolization procedures and is expected to catalyze further physician adoption.
• 1mo ago AI analysis › Press Release
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
TriSalus Life Sciences announced that CEO Mary Szela and CFO David Patience will attend the H.C. Wainwright & Company 28th Annual Global Investment Conference.
Management will participate in one-on-one meetings on September 14 and 15, and a Fireside chat is scheduled for September 14 at 5:00 p.m. ET.
A webcast replay of the chat will be available on the TriSalus investor website for 90 days following the event.
• 2mo ago AI analysis › Press Release
TriSalus Life Sciences Reports Second Quarter 2026 Results
TriSalus reported Q2 revenue of $11.4 million, up 1.7% year-over-year, and maintained full-year revenue guidance of $54 million to $57 million.
Gross margins expanded to 86.8% while operating losses widened to $9.8 million due to increased investment in sales and marketing infrastructure.
The company ended the quarter with $46.3 million in cash, bolstered by a $46 million equity offering in the first quarter, which it believes funds operations into the future.
• 2mo ago AI analysis › Press Release
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
TriSalus Life Sciences announced that CEO Mary Szela and CFO David Patience will attend the Canaccord Genuity 46th Annual Growth Conference.
Management will participate in one-on-one meetings on August 11 and 12, followed by a fireside chat on August 12 at 8:30 a.m. ET.
A webcast replay of the presentation will be available on the company's investor website for 90 days following the event.
• 3mo ago AI analysis › Press Release
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences scheduled a conference call for August 6, 2026, at 4:30 PM ET to discuss its second quarter 2026 financial results.
The company plans to issue a press release detailing the financial results prior to the start of the call.
Investors can register online to receive dial-in details and a PIN, with a live webcast available on the company's investor relations website.
• 3mo ago AI analysis › Press Release
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
TriSalus Life Sciences announced a virtual KOL event on June 24 to discuss new real-world evidence for its Pressure-Enabled Drug Delivery (PEDD) technology in liver cancer.
A newly published study showed that PEDD delivered a 48% improvement in drug delivery to target tumors and reduced hospital readmissions by 61% compared to conventional embolization.
Dr. Alexander Misono of Hoag Hospital will present clinical experience with the TriNav Infusion System, highlighting the technology's ability to reduce off-target complications.
• 4mo ago AI analysis › Press Release ● Major
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
businesswire.com • 5mo ago Press Release
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
businesswire.com • 5mo ago Press Release
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
TriSalus Life Sciences announced the initiation of the PREDICTT clinical trial to evaluate its Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic liver tumors.
The investigator-led study at The University of Texas MD Anderson Cancer Center will enroll approximately 20 patients to assess how the TriNav Infusion System impacts tumor targeting and radiation dose distribution when used with Y90 radioembolization.
Management highlighted the collaboration with MD Anderson as a critical step in generating clinical evidence to redefine the delivery of Y90 therapies.
• 5mo ago AI analysis › Press Release
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
TriSalus Life Sciences announced it will host a conference call on May 12, 2026, to discuss its financial results for the first quarter of fiscal 2026.
The call is scheduled for 4:30 PM ET, with a press release containing the actual financial data expected to be issued prior to the event.
The company focuses on oncology, integrating its proprietary Pressure-Enabled Drug Delivery technology with investigational immunotherapeutics to treat solid tumors.
• 6mo ago AI analysis › Press Release
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
businesswire.com • 6mo ago 
